Key facts
- This page summarizes Katherine Cocca Atkinson's Form 3 filing for Evofem Biosciences, Inc. (EVFM).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 07 Jun 2022, 08:45.
Katherine Cocca Atkinson - 31 May 2022 Form 3 Insider Report for Evofem Biosciences, Inc. (EVFM)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- EVFM
- Reported as of
- 31 May 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Justin J. File
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Katherine Cocca Atkinson filed Form 3 for Evofem Biosciences, Inc. (EVFM) on 07 Jun 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EVFM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 16,667
- Date
- 31 May 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EVFM
holding
Derivative
Stock option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 31 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,000
- Exercise price
- $6.27
- Footnotes
- F2
EVFM
holding
Derivative
Stock option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 31 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 6,667
- Exercise price
- $7.34
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2022.
Footnote F2
The shares of common stock exercisable pursuant to the option will vest as follows: 25% will vest after the first year year of service for the Issuer measured from November 22, 2021, 75% will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from November 22, 2022.
Footnote F3
The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 18, 2022.